Table 4.
Characteristics, measurements and pharmacotherapy of patients in HF stage C at the study visit according to left ventricular ejection fraction
| Left ventricular ejection fraction | <40% | 40–52% | >52% | p |
|---|---|---|---|---|
| N (%) | 18 (8.4) | 43 (20.1) | 153 (71.5) | |
| Age year, mean (SD) | 69 (8.6) | 69 (9.3) | 67 (9.2) | 0.4091 |
| Males, n (%) | 17 (94.4) | 36 (83.7) | 117 (76.5) | 0.162 |
| NYHA class, n (%) | 0.1042 | |||
| I | 5 (29.4) | 9 (21.4) | 53 (35.1) | |
| II | 5 (29.4) | 20 (47.6) | 66 (43.7) | |
| III | 5 (29.4) | 12 (28.6) | 30 (19.9) | |
| IV | 2 (11.8) | 1 (2.4) | 2 (1.3) | |
| Hs-TnT, median (IQR) | 14.3 (8.6–22.9) | 12.3 (8.1–17.8) | 8.9 (6.7–13.0) | 0.0013 |
| NT-proBNP, median (IQR) | 783 (371.5–1960.5) | 495 (255.5–1061.8) | 189 (86.5–401.0) | <0.0013 |
| Beta blocker, n (%) | 18 (100) | 38 (88.4) | 125 (81.7) | 0.0852 |
| ACEi/ARB, n (%) | 16 (88.9) | 36 (83.7) | 125 (81.7) | 0.8722 |
| MRA, n (%) | 3 (16.7) | 7 (16.3) | 7 (4.6) | 0.0112 |
| Loop diuretic, n (%) | 12 (66.7) | 21 (48.8) | 35 (22.9) | <0.0012 |
| Thiazide diuretic, n (%) | 2 (11.1) | 1 (2.3) | 37 (24.2) | 0.0012 |
| Glycoside, n (%) | 3 (16.7) | 4 (9.3) | 7 (4.6) | 0.0742 |
N = 225, age 68.1 (9.1) years, males 180 (80%)
NYHA New York Heart Association functional class, hsTNT high sensitive troponin T, NT-proBNP N-terminal pro B-type natriuretic peptide, ACEi/ARB angiotensin-converting-enzyme inhibitor/angiotensin-receptor blocker, MRA mineralocorticoid receptor antagonist, GAI-3 Guideline Adherence Indicator: number of drugs indicated divided by number of drugs prescribed according to 2008 ESC HF guideline [2]
1ANCOVA
2Fisher’s exact test
3Kruskal-Wallis test